Imetelstat for myelodysplastic or myeloproliferative neoplasms
Treatments studied
Part of Blood & lymphatic clinical trials.
This study tests an experimental drug called imetelstat for people with certain types of MDS/MPN that haven't responded to other treatments. It aims to see if the drug can help improve blood counts and reduce symptoms like an enlarged spleen.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of an MDS/MPN condition like CMML-1, CMML-2, or a related disorder.
- If you have CMML, you need to have tried standard treatments like hydroxyurea or aza/decitabine and they didn't work, or you had side effects.
- You must have certain low blood counts (like anemia) or an enlarged spleen, or a high platelet count.
- You must be in good enough overall health to carry out daily activities (ECOG score 0-2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a mix of medicines (cladribine, low-dose cytarabine, and venetoclax) alternated with azacitidine and venetoclax to treat higher-risk CMML or MDS after prior treatment or when standard treatment may not work well. It may help by improving blood counts and controlling the disease.
This trial tests a new drug called imetelstat combined with two chemotherapy drugs (fludarabine and cytarabine) for children and teens with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or juvenile myelomonocytic leukemia (JMML) that has come back or not responded to treatment. The goal is to find the safest dose of imetelstat and see if it helps control the cancer.
This trial tests a drug called pacritinib in people with myelodysplastic syndromes (MDS) or MDS/myeloproliferative neoplasms (MDS/MPN). The drug targets several proteins that may help control the disease, especially for those who have not responded to other treatments.
This trial compares three different medicines to see which works best for people with a blood condition called myelodysplasia (also called MDS) that causes anemia. It aims to find the safest and most effective option to improve blood counts and reduce symptoms like tiredness or shortness of breath.
This study tests a new drug, momelotinib, for people with a low-risk form of myelodysplastic syndrome (MDS) who need red blood cell transfusions and have already tried one other treatment (like ESAs or luspatercept). The goal is to see if momelotinib can help reduce transfusion needs.
This Phase 1 trial tests whether selumetinib and azacitidine can help people with high-risk chronic blood cancers. You may qualify if your disease is higher risk and has either come back, not responded, or needs treatment because of low blood counts or other concerning features.
Hear when a new Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.